Global Blood Therapeutics Inc (NASDAQ:GBT) – Analysts at Wedbush reduced their Q2 2019 earnings per share (EPS) estimates for Global Blood Therapeutics in a research report issued to clients and investors on Tuesday, June 11th. Wedbush analyst L. Moussatos now forecasts that the company will post earnings of ($0.95) per share for the quarter, down from their previous forecast of ($0.05). Wedbush has a “Buy” rating and a $107.00 price objective on the stock. Wedbush also issued estimates for Global Blood Therapeutics’ Q3 2019 earnings at ($0.97) EPS, Q4 2019 earnings at ($0.99) EPS, FY2019 earnings at ($3.79) EPS, Q1 2020 earnings at ($0.99) EPS, Q2 2020 earnings at ($0.99) EPS, Q3 2020 earnings at ($0.90) EPS, Q4 2020 earnings at ($0.82) EPS, FY2020 earnings at ($3.70) EPS, FY2021 earnings at ($1.96) EPS, FY2022 earnings at $1.27 EPS and FY2023 earnings at $5.59 EPS.
Global Blood Therapeutics (NASDAQ:GBT) last released its earnings results on Wednesday, May 8th. The company reported ($0.87) EPS for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.07.
Shares of NASDAQ GBT opened at $57.52 on Friday. Global Blood Therapeutics has a twelve month low of $30.15 and a twelve month high of $63.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 14.51 and a quick ratio of 14.51.
A number of institutional investors and hedge funds have recently bought and sold shares of GBT. Truvestments Capital LLC bought a new stake in Global Blood Therapeutics in the 1st quarter valued at $33,000. Kore Private Wealth LLC bought a new stake in Global Blood Therapeutics during the 1st quarter worth about $53,000. Lindbrook Capital LLC bought a new stake in Global Blood Therapeutics during the 4th quarter worth about $55,000. Strs Ohio bought a new stake in Global Blood Therapeutics during the 4th quarter worth about $65,000. Finally, Bank of Montreal Can lifted its position in Global Blood Therapeutics by 61.9% during the 4th quarter. Bank of Montreal Can now owns 1,582 shares of the company’s stock worth $65,000 after buying an additional 605 shares in the last quarter.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
See Also: What is a conference call?
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.